Publications by authors named "Roy Hershenson"
Article Synopsis
- Diabetes mellitus (DM) is linked to serious heart conditions like coronary artery disease (CAD) and heart failure, but SGLT2 inhibitors (SGLT2i) can help lower cardiovascular risks in these patients.
- A study examined how the SGLT2i empagliflozin affects circulating endothelial progenitor cells (cEPCs) in DM patients with stable CAD over three months.
- Results showed a significant increase in both the levels and function of cEPCs after three months of treatment, suggesting that empagliflozin may offer cardioprotective benefits beyond blood sugar control.
Brain natriuretic peptide is an established, surrogate follow-up marker, strongly correlated with heart failure severity. Several other biomarkers and tests are useful for assessing the prognosis of patients with HF, such as oxidized low-density lipoprotein antibodies and C-reactive protein. Some inflammatory cells, including monocytes, lymphocytes, and neutrophils, are involved in coronary heart disease and may be useful for prognosis also.
View Article and Find Full Text PDF